Healthcare: Eli Lilly’s Big Announcement, Plus GlaxoSmithKline Cozies Up to 23andMe

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 25 July 2018

⏱️ 22 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

It’s big pharma week! First, we discuss Eli Lilly’s second quarter earnings and its decision to spin-off its animal health business. Then, we explain why GlaxoSmithKline became an investor in the DNA screening company, 23andMe.

Transcript

Click on a timestamp to play from that location

0:00.0	This episode of Industry Focus is brought to you by Sinios Health, a new fully integrated
0:04.5	bio-pharmaceutical Solutions Organization that's the result of a merger between Inc. research and
0:09.6	Inventive Health. Sinios Health is focused on a simple end goal, shortening the distance from lab to life.
0:16.3	To learn more, visit sinios Health.com.
0:18.7	Sineus.
0:21.7	Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.
0:27.0	Today is July 25th. I'm your host Christine Hargis and I'm joined by Fool.com contributor Todd Campbell via Skype.
0:33.0	On this health care episode we're covering Big Pharma earnings and announcements.
0:37.0	First we'll talk Eli Lilly, ticker L-L-Y,
0:40.0	and then we'll move to GlaxoSmith Klein, ticker G.S.K.
0:44.0	Eli Lillie is first and foremost a diabetes-focused company
0:48.0	and they are massive, but they also make drugs for cancer
0:51.0	and some other diseases, and and as will become important later in
0:54.8	our discussion they have a pretty sizable animal health division.
0:58.8	Lily reported earnings yesterday and shares got a 5% left.
1:03.0	Eli Lilly launched the very first, Christine, the very first commercial insulin for diabetes
1:09.4	patients.
1:10.4	They did that back in 1923.
1:12.0	So it's probably not surprising to find out that they today
1:15.1	remain the second largest producer of diabetes drugs. They actually get
1:20.2	about 44% of their revenue from diabetes treatments.
1:26.5	So I think it probably just to set the stage might be helpful for our listeners to get a
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.